An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Starting soon · Phase 3

Conditions studied: Epidermolysis Bullosa (EB)

In brief

The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.

Key facts

Study ID
NCT07482813
Run by
Paradigm Therapeutics
People needed
80
Starts
2026-07-15
Expected to finish
2027-08-19
Last updated by the study team
2026-03-19

Who can join

Age: 0 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.